15.42
+3.77%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lyell Immunopharma
From its filings with the US Securities and Exchange Commission
Lyell Immunopharma is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LYEL. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $36,000 and a net loss of $274.4m. At that date it held total assets of $340.1m and shareholders' equity of $248.2m.
We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with cancer. Our goal is to fully realize the curative potential of cell therapy for patients with hematologic malignancies and solid tumors. To achieve this, we are pioneering novel approaches designed to generate T‑cell therapies that drive long-lasting clinical responses. Our CAR T-cell product candidates start with the identification of promising cancer targets. We then engineer the patient’s own living immune cells and arm them with our innovative enhancements, including CAR constructs, technologies and manufacturing protocols that are designed to endow T cells with more potent cancer cell killing capabilities.
In hematologic malignancies, we are focused on delivering therapies that provide patients meaningfully improved outcomes over currently approved, first-generation CD19 CAR T-cell products. Our lead product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is a dual-targeting CD19/CD20 CAR T-cell therapy designed to increase complete response rates and prolong the duration of response as compared to the approved CD19‑targeted CAR T-cell therapies. Ronde-cel is designed with a true ‘OR’ logic gate to target B cells that express either CD19 or CD20 with full potency and is manufactured with a process that enriches for CD62L‑positive cells to generate more naïve and central memory CAR T cells with enhanced stemlike features and antitumor activity.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jun 2021
- Employees
- 161
- Website
- lyell.com ↗
- Head office
- 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Richard KlausnerChairman of the Board, since 2021$288,069
- Dr. Lynn SeelyPresident, Chief Executive Officer, Interim Principal Financial Officer, Director, since 2021$1.5m
- Mr. Stephen HillChief Operating Officer$1.3m
- Dr. Gary LeeChief Scientific Officer$2.2m
- Ms. Catherine FriedmanLead Independent Director, since 2018$307,842
- Dr. Mark BachledaDirector
- Dr. Otis BrawleyIndependent Director$265,335
- Dr. Elizabeth NabelIndependent Director$269,202
- Dr. Sumant RamachandraIndependent Director$177,267
- Mr. William RieflinIndependent Director$279,889
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 81
- Social
- 99
- Governance
- 36
- Women in the workforce
- 49.3%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lyell Immunopharma's LYL119 targets ROR1 CAR T-cell therapy for enhanced cytotoxicity in solid tumors.
- The company's technologies address T-cell exhaustion and lack of durable stemness in solid tumor treatments.
- Lyell's product candidates LYL797, LYL845, and LYL119 apply to multiple T cell modalities including CAR and TIL therapies.
Weaknesses
- Lyell Immunopharma's 161 employees are fewer than the 274 full-time employees mentioned in the business description.
- The company's IPO on 17 June 2021 may indicate limited market traction compared to established biotech firms.
- Lyell's focus on cell-based immunotherapies for solid tumors faces high development costs and regulatory hurdles.
Opportunities
- The growing biotechnology sector in the US offers expansion opportunities for Lyell's cell-based immunotherapies.
- Increasing demand for CAR T-cell therapies in oncology presents a market opportunity for LYL119.
- Collaborations with pharmaceutical companies could accelerate Lyell's product development and commercialization.
Threats
- Competition from established biotech firms in the US Health Care sector poses a significant threat.
- Regulatory challenges in the US biotechnology industry could delay product approvals.
- High costs of cell therapy development may limit Lyell's ability to scale operations effectively.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.